BN83495 in Prostate Cancer

• Status: Completed
• Trial end date: 2011-02-01

Summary

The purpose of the study is to evaluate the pharmacodynamic profile and safety of BN83495 in patients with prostate cancer with disease progression while on androgen ablative therapy

• Phase: Phase 1

Details

• Lead Sponsor: Ipsen